Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
111. |
ECCT/15/12/02 | The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial A Multi Centre, Open label, Randomized Clinical Trial, Comparing HIV incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone Acetate, Levernogestrel (LNG) implant and Copper Intrauterine Devices (IUD). Short Title : The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial |
Principal Investigator(s) 1. Prof Elizabeth Anne Bukusi Site(s) in Kenya KEMRI-RCTP Study center , Lumumba |
View |
112. |
ECCT/21/09/04 | Recombinant COVID-19 Vaccine A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells) for the prevention of COVID-19 in adults aged 18 years and older |
Principal Investigator(s) 1. Sylvester Kimaiyo Site(s) in Kenya 1. KAVI-Institute of Clinical Research (Nairobi City county) 2. Moi Teaching and Referral Hospital (Uasin Gishu county) 3. Kenya Medical Research Institute, Kilifi (Kilifi county) |
View |
113. |
ECCT/15/12/05 | Post-discharge Malaria Chemoprevention(PMC) study Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-centre, parallel-group, two-arm randomised placebo controlled superiority trial |
Principal Investigator(s) 1. Titus Kwambai 2. Simon Kariuki Site(s) in Kenya 1. Siaya County Referral Hospital (Siaya county) 2. Homa Bay County Referral Hospital (Homa Bay county) 3. Migori County Referral Hospital (Migori county) 4. Busia County Referral Hospital (Busia county) |
View |
114. |
ECCT/24/06/05 | SII-qHPV Vaccine Study A Phase-3b, partially double-blind, randomized, multi-country clinical study to evaluate the immunogenicity, safety, and reactogenicity of SIIPL qHPV vaccine (CERVAVAC®) in women living with HIV aged 15-25 years. |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya 1. KEMRI-CCR PHRD Thika (Kiambu county) 2. KEMRI - CCR Nairobi (Nairobi City county) |
View |
115. |
ECCT/22/01/04 | SKYSCRAPER 07 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Mansoor Saleh Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |